Physician profile
Daniel C Ketterer
NPI 1134393796
$15,362.29
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,091 · 2020: $3,110 · 2021: $1,529 · 2022: $1,362 · 2023: $1,106 · 2024: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.92 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,157.72 | 2019-2024 | |
| Allergan, INC. | $2,649.81 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $2,181.85 | 2019-2024 | Nuzyra |
| Viiv Healthcare Company | $1,761.18 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $639.67 | 2019-2024 | Dificid, Delstrigo, Zerbaxa |
| Insmed, INC. | $625.04 | 2019-2024 | Arikayce |
| Melinta Therapeutics, LLC | $466.64 | 2019-2024 | Orbactiv, Kimyrsa, Vabomere |
| La Jolla Pharmaceutical Company | $408.48 | 2021-2024 | Xerava |
| Janssen Biotech, INC. | $346.22 | 2019-2023 | Symtuza |
| Abbvie INC. | $323.60 | 2021-2024 | |
| Theratechnologies INC. | $245.95 | 2019-2024 | Egrifta, Trogarzo |
| Cumberland Pharmaceuticals, INC. | $129.74 | 2019-2024 | Vibativ |
| Shionogi INC | $94.43 | 2022-2023 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $71.80 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $65.84 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $36.04 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $27.42 | 2020 | |
| Octapharma USA, INC. | $24.14 | 2022 | |
| Astellas Pharma US INC | $22.77 | 2020 | |
| Ferring Pharmaceuticals INC. | $22.55 | 2023 | Rebyota |
| Dynavax Technologies Corporation | $17.31 | 2019 | |
| Emd Serono, INC. | $16.40 | 2021 | |
| Argentum Medical | $14.86 | 2023 | |
| Napo Pharmaceuticals INC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ketterer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.